Clinical trial
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast…
NCT00027989 · Pharmatech Oncology, Industry · Unknown status
Key facts
| NCT number | NCT00027989 |
|---|---|
| Title | Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer |
| Official title | An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer |
| Lead sponsor | Pharmatech Oncology, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride |
| Start date | Dec 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: